Bayesian Capital Management’s CRISPR Therapeutics CRSP Stock Holding History

Bayesian Capital Management’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-8,800	Closed	-$413K	–	740
2024 Q3	$413K	Buy	8,800 +2,600	+42%	+$132K	0.05%	415
2024 Q2	$335K	Sell	6,200 -34,800	-85%	-$2.01M	0.04%	481
2024 Q1	$2.79M	Buy	+41,000	New	+$2.94M	0.27%	97
2023 Q3	–	Sell	-18,129	Closed	-$1.02M	–	746
2023 Q2	$1.02M	Buy	+18,129	New	+$1.03M	0.11%	254
2023 Q1	–	Sell	-12,792	Closed	-$520K	–	848
2022 Q4	$520K	Buy	+12,792	New	+$679K	0.08%	350
2022 Q2	–	Sell	-5,000	Closed	-$314K	–	833
2022 Q1	$314K	Buy	+5,000	New	+$314K	0.05%	506
2020 Q2	–	Sell	-6,200	Closed	-$263K	–	567
2020 Q1	$263K	Buy	+6,200	New	+$320K	0.06%	504
2019 Q3	–	Sell	-4,594	Closed	-$216K	–	544
2019 Q2	$216K	Sell	4,594 -4,906	-52%	-$196K	0.04%	425
2019 Q1	$339K	Buy	+9,500	New	+$328K	0.07%	366

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bayesian Capital Management's CRSP Position: Q4 2024 in Review

Bayesian Capital Management sold out of CRISPR Therapeutics (CRSP) in Q4 2024, closing a stake of 8,800 shares — an estimated $413K sold.

Bayesian Capital Management first reported a position in CRSP in Q1 2019 and held it in 9 quarters. The position peaked at $2.79M in Q1 2024. 404 funds tracked by Wall St. Rank hold CRSP as of Q4 2024.

Bayesian Capital Management reported no remaining CRISPR Therapeutics position as of Q4 2024 after selling out during the quarter.
Bayesian Capital Management sold 8,800 CRISPR Therapeutics shares in Q4 2024, an estimated $413K.
Bayesian Capital Management first reported a position in CRISPR Therapeutics in Q1 2019 and held it in 9 quarters.
Bayesian Capital Management's CRISPR Therapeutics position peaked at $2.79M in Q1 2024.
404 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q4 2024.

Based on Bayesian Capital Management's 13F filing for Q4 2024, filed 14 Feb 2025.